Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
Identifieur interne : 001789 ( PubMed/Corpus ); précédent : 001788; suivant : 001790Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
Auteurs : P. Joly ; A. Lampert ; E. Thomine ; P. LauretSource :
- Journal of the American Academy of Dermatology [ 0190-9622 ] ; 1991.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : 5-Hydroxytryptophan, Carbidopa.
- chemically induced : Eosinophilia-Myalgia Syndrome, Scleroderma, Localized.
- drug therapy : Depression, Parkinson Disease.
- Aged, Chronic Disease, Drug Therapy, Combination, Humans, Male.
PubMed: 1918474
Links to Exploration step
pubmed:1918474Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.</title><author><name sortKey="Joly, P" sort="Joly, P" uniqKey="Joly P" first="P" last="Joly">P. Joly</name><affiliation><nlm:affiliation>Department of Dermatology, Hôpital Charles Nicolle, Rouen, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lampert, A" sort="Lampert, A" uniqKey="Lampert A" first="A" last="Lampert">A. Lampert</name></author><author><name sortKey="Thomine, E" sort="Thomine, E" uniqKey="Thomine E" first="E" last="Thomine">E. Thomine</name></author><author><name sortKey="Lauret, P" sort="Lauret, P" uniqKey="Lauret P" first="P" last="Lauret">P. Lauret</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1991">1991</date><idno type="RBID">pubmed:1918474</idno><idno type="pmid">1918474</idno><idno type="wicri:Area/PubMed/Corpus">001789</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001789</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.</title><author><name sortKey="Joly, P" sort="Joly, P" uniqKey="Joly P" first="P" last="Joly">P. Joly</name><affiliation><nlm:affiliation>Department of Dermatology, Hôpital Charles Nicolle, Rouen, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lampert, A" sort="Lampert, A" uniqKey="Lampert A" first="A" last="Lampert">A. Lampert</name></author><author><name sortKey="Thomine, E" sort="Thomine, E" uniqKey="Thomine E" first="E" last="Thomine">E. Thomine</name></author><author><name sortKey="Lauret, P" sort="Lauret, P" uniqKey="Lauret P" first="P" last="Lauret">P. Lauret</name></author></analytic><series><title level="j">Journal of the American Academy of Dermatology</title><idno type="ISSN">0190-9622</idno><imprint><date when="1991" type="published">1991</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5-Hydroxytryptophan (adverse effects)</term><term>Aged</term><term>Carbidopa (adverse effects)</term><term>Chronic Disease</term><term>Depression (drug therapy)</term><term>Drug Therapy, Combination</term><term>Eosinophilia-Myalgia Syndrome (chemically induced)</term><term>Humans</term><term>Male</term><term>Parkinson Disease (drug therapy)</term><term>Scleroderma, Localized (chemically induced)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>5-Hydroxytryptophan</term><term>Carbidopa</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Eosinophilia-Myalgia Syndrome</term><term>Scleroderma, Localized</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depression</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Chronic Disease</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Male</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1918474</PMID><DateCreated><Year>1991</Year><Month>11</Month><Day>12</Day></DateCreated><DateCompleted><Year>1991</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0190-9622</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>2 Pt 1</Issue><PubDate><Year>1991</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of the American Academy of Dermatology</Title><ISOAbbreviation>J. Am. Acad. Dermatol.</ISOAbbreviation></Journal><ArticleTitle>Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.</ArticleTitle><Pagination><MedlinePgn>332-3</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joly</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Hôpital Charles Nicolle, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lampert</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Thomine</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Lauret</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Acad Dermatol</MedlineTA><NlmUniqueID>7907132</NlmUniqueID><ISSNLinking>0190-9622</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>C1LJO185Q9</RegistryNumber><NameOfSubstance UI="D006916">5-Hydroxytryptophan</NameOfSubstance></Chemical><Chemical><RegistryNumber>MNX7R8C5VO</RegistryNumber><NameOfSubstance UI="D002230">Carbidopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006916" MajorTopicYN="N">5-Hydroxytryptophan</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002230" MajorTopicYN="N">Carbidopa</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016603" MajorTopicYN="N">Eosinophilia-Myalgia Syndrome</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012594" MajorTopicYN="N">Scleroderma, Localized</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1918474</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001789 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001789 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:1918474
|texte= Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:1918474" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |